|
| 36404491 | Impact of the COVID-19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race. | Cancer Med | 2023 |
| 37961519 | Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages. | bioRxiv | 2023 |
| 37587913 | Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. | Cancer Res Commun | 2023 |
| 37265453 | Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer. | Clin Cancer Res | 2023 |
| 36918220 | Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. | J Immunother Cancer | 2023 |
| 36693175 | Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer. | Clin Cancer Res | 2023 |
| 36609389 | A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). | | 2023 |
| 36273232 | Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer. | Sci Rep | 2022 |
| 36055301 | Call for action: expanding global access to hereditary cancer genetic testing. | Lancet Oncology, The | 2022 |
| 36001024 | Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. | Cancer Discov | 2022 |
| 35515356 | Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab. | Breast Cancer: Targets and Therapy | 2022 |
| 35314693 | A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis. | npj Breast Cancer | 2022 |
| 34776060 | Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies. | Surgical Oncology Clinics of North America | 2022 |
| 34550428 | Correction to: Coâ¿¿clinical FDGâ¿¿PET radiomic signature in predicting response to neoadjuvant chemotherapy in tripleâ¿¿negative breast cancer. | Eur J Nucl Med Mol Imaging | 2022 |
| 36585404 | A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. | | 2022 |
| 34328530 | Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. | Eur J Nucl Med Mol Imaging | 2022 |
| 36332363 | Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer. | EBioMedicine | 2022 |
| 33792894 | Racial differences in no-show rates for screening mammography. | Cancer | 2021 |
| 33219484 | Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA). | Breast Cancer Res Treat | 2021 |
| 34662201 | Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists. | Journal of Clinical Oncology | 2021 |
| 34173924 | Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. | Breast Cancer Res Treat | 2021 |
| 33970392 | Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy using Biomarkers, Ultrasound, and Diffuse Optical Tomography. | Breast Cancer Research and Treatment | 2021 |
| 32135512 | Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy. | Journal of the National Comprehensive Cancer Network : JNCCN | 2020 |
| 32891051 | Optimal co-clinical radiomics: Sensitivity of radiomic features to tumour volume, image noise and resolution in co-clinical T1-weighted and T2-weighted magnetic resonance imaging. | eBioMedicine | 2020 |
| 32856383 | Characteristics of male triple negative breast cancer: A population-based study. | Breast Journal | 2020 |
| 32651755 | Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HRâ¿¿+â¿¿breast cancer and negative axillary ultrasound. | Breast Cancer Research and Treatment | 2020 |
| 31325073 | Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations. | Breast Cancer Res Treat | 2019 |
| 31218477 | Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. | Breast Cancer Research and Treatment | 2019 |
| 30787127 | Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. | J Natl Compr Canc Netw | 2019 |
| 31727116 | Associations of race and ethnicity with risk of developing invasive breast cancer after lobular carcinoma in situ. | Breast Cancer Res | 2019 |
| 31536530 | Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database. | PLoS ONE | 2019 |
| 29706375 | Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. | Lancet Oncol | 2018 |
| 30350491 | Compact ultrasound-guided diffuse optical tomography system for breast cancer imaging. | Journal of Biomedical Optics | 2018 |
| 27915434 | Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians. | Breast Cancer Research and Treatment | 2017 |
| 28874413 | A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast Cancer. | Clin Cancer Res | 2017 |
| 28270497 | NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. | Clin Cancer Res | 2017 |
| 26621531 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. | Hum Genet | 2016 |
| 26563128 | A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. | Clin Cancer Res | 2016 |
| 26304062 | Comparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and Costs. | Medical Decision Making | 2016 |
| 27569274 | Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. | Clinical Breast Cancer | 2016 |
| 27212005 | Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 N0 Breast Cancer and Normal Axillary Ultrasound. | Journal of the American College of Surgeons | 2016 |
| 26779976 | Axillary Ultrasound Accurately Excludes Clinically Significant Lymph Node Disease in Patients With Early Stage Breast Cancer. | Annals of Surgery | 2016 |
| 26730210 | Managing breast cancer in younger women: challenges and solutions. | Breast Cancer: Targets and Therapy | 2016 |
| 25483625 | US breast cancer mortality trends in young women according to race. | Cancer | 2015 |
| 26269605 | CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer. | Molecular Cancer Therapeutics | 2015 |
| 25678364 | Reply to Differences in 25-hydroxyvitamin D concentrations may explain most of the black-white breast cancer disparities noted in young women. | Cancer | 2015 |
| 24289215 | Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study. | European Journal of Cancer Care | 2014 |
| 23983689 | Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. | Journal of Oncology | 2013 |
| 23535731 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. | Nat Genet | 2013 |
| 23535733 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci. | Nat Genet | 2013 |